Skip to main content
. 2024 Feb 24;130(13):2351–2360. doi: 10.1002/cncr.35258

TABLE 4.

Patients’ characteristics according to risk group.

No. (%)
Characteristic Low risk, N = 176 Medium risk, N = 701 High risk, N = 423 Very high risk, N = 361
Age at diagnosis Birth to 3 years 6 (3) 256 (36) 23 (5) 182 (50)
3–10 years 102 (58) 277 (40) 331 (78) 61 (17)
10 years and older 68 (39) 168 (24) 69 (17) 118 (33)
Tumor size ≤5 cm 147 (83) 438 (62) 144 (34) 86 (24)
>5 cm 29 (17) 263 (38) 279 (66) 275 (76)
Primary site Extremities/HNPM/other sites 80 (11) 346 (82) 353 (98)
GUBP/HNnoPM/orbit 21 (12) 451 (64) 54 (13) 8 (2)
GUnoBP/bile ducts 155 (88) 170 (24) 23 (5)
IRS group I 128 (73) 73 (10) 3 (1)
II 48 (27) 142 (20) 12 (3) 2 (1)
III 486 (69) 408 (96) 359 (99)
Fusion status Negative 176 (100) 661 (94) 360 (85) 196 (54)
Positive 40 (6) 63 (15) 165 (46)
Age/tumor size Birth to 3 years/>5 cm 6 (3) 112 (16) 3 (1) 113 (31)
Birth to 3 years/≤5 cm 144 (20) 20 (5) 69 (19)
3–10 years/≤5 cm 79 (45) 194 (28) 104 (25) 17 (5)
3–10 years/>5 cm 23 (13) 83 (12) 227 (54) 44 (12)
10 years and older/≤5 cm 68 (39) 100 (14) 20 (5)
10 years and older/>5 cm 68 (10) 49 (12) 118 (33)
EFS probability, % 3 years [95% CI] 94.1 [89.4–96.8] 80.6 [77.4–83.3] 68.4 [63.7–72.6] 54.3 [48.9–59.3]
5 years [95% CI] 94.1 [89.4–96.8] 78.4 [75.1–81.3] 65.2 [60.4–69.6] 52.1 [46.8–57.2]
Type of event Dead 2 (1) 3 (2)
Local‐regional 6 (55) 96 (64) 66 (44) 77 (43)
Metastases progression 4 (36) 24 (16) 40 (26) 60 (34)
Other 1 (9) 10 (7) 13 (9) 5 (3)
Progressive disease 19 (13) 29 (19) 36 (20)
OS probability 3 years [95% CI] 98.8 [95.2–99.7] 94.0 [92.0–95.6] 78.7 [74.5–82.4] 72.5 [67.5–76.8]
5 years [95% CI] 97.2 [92.7–99.0] 91.5 [89.0–93.4] 74.3 [69.7–78.3] 60.8 [55.4–65.9]

Abbreviations: CI, confidence interval; EFS, event‐free survival; GUBP, genitourinary bladder‐prostate; HNnoPM, head and neck nonparameningeal; HNPM, head and neck parameningeal; IRS, Intergroup Rhabdomyosarcoma Studies; OS, overall survival.